Neoadjuvant Antiandrogen Therapy With or Without MEK or SRC Inhibition for Unfavorable-risk Prostate Cancer: A Phase 2 Randomized Clinical Trial
{{output}}
Background and objective: It is thought that androgen deprivation therapy (ADT) resistance and subsequent prostate cancer progression via epithelial-mesenchymal transition (EMT) is induced by the SRC and MEK pathways. We hypothes... ...
